Hedy Smith is a Hematology physician. OpenAlex indexes 59 publications with 1,279 citations (h-index 18); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
830 Harrison Avenue
Moakley, 3rd Floor
Boston, MA 02118
Telephone
617-638-6428Registry record last updated 27 Sept 2017.
Clinical trials
- Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)
Sponsor: Deciphera Pharmaceuticals, LLC
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
31 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Agios Pharmaceuticals, Inc.Program year20256 payments
- Chiesi USA, Inc.Program year20251 payment
- Celgene CorporationProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
44.8%Antimetabolite14.9%Hydroxyurea100%Part D≥11 patientsThalidomide Analog10.1%Revlimid100%Part D<11 patients+ 3 more classes in this area
Nervous system
27.1%Opioid Agonist20.4%Oxycodone Hcl63%Methadone Hcl19%Hydromorphone Hcl18%Part D<11 patientsBenzodiazepine3.4%Clonazepam100%Part D<11 patients+ 1 more class in this area
Dermatology
15.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor15.9%Acyclovir100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Effects of sickle trait on maternal and perinatal outcomes among pregnant women
Blood Vessels Thrombosis & Hemostasis
2025 - Correlation Between VOC and Cognitive Function Using the NIH ToolBox in SCD
Journal of sickle cell disease.
2024 - PB1538 Pregnancy Outcomes in Women with Sickle Cell Trait
Research and Practice in Thrombosis and Haemostasis
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Tait Shanafelt, MD
Palo Alto University
Robert Bast, MD
The University of Texas MD Anderson Cancer Center
Thomas Witzig, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”